



Vivimed

Date: 14/11/2018

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

The Board of Directors of the Company at its meeting held on November 14, 2018 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved the submission of the Unaudited Financial Results (Standalone & Consolidated) for the Quarter and half year ended September 30, 2018 attached herewith;
2. Auditors's Limited Review Report on the Unaudited Financial Statements of the Company for the quarter and half year ended September 30, 2018.
3. Has re-designated Shri.S.Raghunandan, from Whole-time Director to Whole-time Director -cum- Chief Financial Officer of the Company with immediate effect.

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

FOR VIVIMED LABS LIMITED


SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Limited.

CIN: L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka - 585 403, India.

T +91 (0) 8482-232045, F +91 (0) 8482-232436

Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

North End, Road No. 2

Banjara Hills, Hyderabad,

Telangana - 500 034, India.

GSTIN: 36AAACV6060A1ZQ

T +91(0) 40-6608-6608, F +91(0) 40-6608-6699

VIVIMED LABS LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2018

Rs in Lakhs

Sl. No.	Particulars	Quarter Ended			H1 FY 18	H1 FY 17	FY 18
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
	Income From Operations						
1	Revenue from operations	36,462.44	35,854.14	28,250.00	72,316.58	60,047.42	1,18,178.83
	Total revenue from operations	36,462.44	35,854.14	28,250.00	72,316.58	60,047.42	1,18,178.83
2	Other income	505.75	574.72	61.24	1,078.45	321.17	557.19
3	Total Revenue (1+2)	36,968.19	36,428.86	28,311.24	73,395.04	60,374.58	1,19,136.01
4	Expenses						
a	Cost of material consumed	15,250.24	15,025.35	11,383.40	30,275.59	23,587.91	48,980.29
b	Purchases of Stock-in-Trade						
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(306.89)	(742.70)	(643.52)	-1,049.59	898.59	(1,012.92)
d	Employee Benefit Expenses	6,582.70	5,798.53	4,438.89	12,381.23	8,715.45	19,345.19
e	Finance Costs	1,759.28	1,928.00	2,135.52	3,687.28	4,558.50	7,923.83
f	Depreciation and Amortisation Expenses	1,957.94	1,586.73	1,608.47	3,544.67	2,864.08	5,641.96
g	Other Expenses	9,915.94	8,892.53	6,810.81	18,808.47	13,938.11	29,686.59
	Total Expenses	35,159.19	32,488.45	25,733.59	67,647.64	54,562.65	1,20,564.94
5	Profit before tax (3-4)	1,806.98	3,940.41	2,577.65	5,747.40	5,811.93	8,571.07
6	Tax expenses						
	Current Taxes	-139.32	1,094.77	330.06	955.45	1,173.88	1,217.93
	Deferred Taxes	118.46	-	40.79	118.46	40.79	-255.81
	Total tax expenses	(20.86)	1,094.77	370.85	1,073.91	1,214.67	962.12
7	Profit for the period /Year before non-controlling interest (5-6)	1,827.84	2,845.65	2,206.80	4,673.49	4,597.27	7,608.95
8	Non-controlling interest						
9	Profit for the period / year (7-8)	1,827.84	2,845.65	2,206.80	4,673.49	4,597.27	7,608.95
10	Other comprehensive income						
	Items that will not be reclassified to profit or loss, net of tax	-	-	-	-	-	(65.68)
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	(65.68)
11	Non-controlling interest	-	-	-	-	-	185.29
12	Other comprehensive income attributable to shareholders(10+11)	-	-	-	-	-	119.61
	Total comprehensive income attributable to:						
	Shareholders of the Company						7,728.56
	Non-controlling interest	1,827.84	2,845.65	2,206.80	4,673.49	4,597.27	-
	Total Comprehensive income	1,827.84	2,845.65	2,206.80	4,673.49	4,597.27	7,543.27
13	Paid up Equity Share Capital	1,650.48	1,650.48	1,639.73	1,650.48	1,639.73	1,650.48
14	Other equity						
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)						
	(a) Basic	2.21	3.45	2.69	5.66	5.61	9.14
	(b) Diluted	2.12	3.31	2.64	5.43	5.50	9.03

1. The above Consolidated Unaudited Financial Results for the Quarter & Half year ended 30.09.2018 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14.11.2018

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Finoso Pharma Pvt Limited (ii) Vivimed Speciality chemicals Pvt Ltd and its wholly owned foreign subsidiaries viz(i) Vivimed Labs USA, Inc.,(ii) Vivimed Labs Mauritius Limited (iii) Vivimed Holdings Limited and its stepdown subsidiaries (iv) Vivimed Labs Europe Limited (v) Vivimed Labs UK Limited, (vi) Vivimed Labs Spain, S.L. (vii) Union Quimica Farmaceutica S.A.U., Spain, (viii) Holiday International Limited, UK & (ix) Uquifa Mexico S.A. de C.V.(x) Vivimed Labs (Mascarene) Ltd (xi) Soncas Chemicals Ltd (xii) Soncas Research Ltd and its wholly owned Indian subsidiary (iii) UQUIFA India Private Limited and its Indian subsidiary (i) Vivimed life sciences Pvt Ltd

3. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 14.11.2018



For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER'2018

Rs in Lakhs

Particulars	3 Months Ended			FY 19 H1	FY 18 H1	FY 18
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)						
a.Speciality Chemicals Business	4,480.67	4,167.55	5,113.28	8,648.22	10,508.64	20,034.63
b.Pharma Business	31,981.77	31,686.59	23,136.72	63,668.37	49,538.78	98,531.39
Total	36,462.44	35,854.14	28,250.00	72,316.58	60,047.42	1,18,566.02
Less: Inter Segment Revenue						
Net sales / Income from Operations	36,462.44	35,854.14	28,250.00	72,316.58	60,047.42	1,18,566.02
2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment						
a.Speciality Chemicals Business	1,534.93	1,365.21	2,203.12	2,900.14	3,729.86	6,223.17
b.Pharma Business	2,031.33	4,503.21	2,510.05	6,534.53	6,640.57	10,271.73
Total	3,566.26	5,868.42	4,713.17	9,434.67	10,370.44	16,494.90
Less: 1.Interest	1,759.28	1,928.00	2,135.52	3,687.28	4,558.50	7,923.83
2.Other Un-allocable Expenditure						
3.Un-allocable Income						
Total Profit Before Tax	1,806.98	3,940.41	2,577.65	5,747.40	5,811.93	8,571.07

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad

Date : 14.11.2018



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2018

Rs in Lakhs

Sl. No	Particulars	Quarter Ended			H1 FY 18	H1 FY 17	FY 18
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
	Income From Operations						
1	Revenue from operations	6,350.49	6,198.53	6,114.65	12,549.02	12,750.25	26,138.59
	Total revenue from operations	6,350.49	6,198.53	6,114.65	12,549.02	12,750.25	26,138.59
2	Other Income	16.33	56.39	0.23	12.12	55.30	192.95
3	Total Revenue (1+2)	6,366.82	6,254.92	6,114.88	12,621.74	12,785.55	26,331.54
4	Expenses						
a	Cost of material consumed	3,957.14	2,998.98	2,414.00	6,956.13	4,966.72	11,494.73
b	Purchases of Stock- in- Trade						
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(1,837.86)	(975.91)	(589.51)	-2,813.77	(708.59)	(2,854.63)
d	Employee Benefit Expenses	848.18	842.82	919.54	1,691.00	1,613.37	3,408.63
e	Finance Costs	1,156.68	1,138.70	1,297.55	2,295.38	2,512.51	5,180.22
f	Depreciation and Amortisation Expenses	442.21	482.89	493.62	925.11	940.69	1,814.36
g	Other Expenses	1,685.63	1,607.94	1,367.68	3,293.56	3,044.88	6,403.01
	Total Expenses	6,251.98	6,095.43	5,902.89	12,347.41	12,369.57	25,446.32
5	Profit before tax (3-4)	114.84	159.49	211.99	274.33	415.98	885.20
6	Tax expenses						
	Current Taxes	41.97	31.90	42.50	73.87	83.30	170.25
	Deferred Taxes	-50.82	-	-	-50.82	-	-271.76
	Total tax expenses	(8.86)	31.90	42.50	23.04	83.30	(101.51)
7	Profit for the period /Year before non-controlling interest (5-6)	123.70	127.59	169.49	251.29	332.68	986.71
8	Non-controlling interest						
9	Profit for the period/ year (7-8)	123.70	127.59	169.49	251.29	332.68	986.71
10	Other comprehensive income						
	Items that will not be reclassified to profit or loss, net of tax						(65.37)
	Items that will be reclassified to profit or loss, net of tax						
	Total other comprehensive income	-	-	-	-	-	(65.37)
11	Non-controlling interest						
12	Other comprehensive income attributable to shareholders(10+11)	-	-	-	-	-	(65.37)
	Total comprehensive income attributable to:						
	Shareholders of the Company						921.34
	Non-controlling Interest	123.70	127.59	169.49	251.29	332.68	-
	Total Comprehensive income	123.70	127.59	169.49	251.29	332.68	921.35
13	Paid up Equity Share Capital	1,650.48	1,650.48	1,639.73	1,650.48	1,639.73	1,650.48
14	Other equity						
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)						
	(a) Basic	0.15	0.15	0.21	0.30	0.41	1.12
	(b) Diluted	0.14	0.15	0.20	0.29	0.40	1.10

1. The above Standalone Unaudited Financial Results for the Quarter & Half year ended September 30, 2018 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14.11.2018. The Financial results are prepared in accordance with the Indian Accounting standards (IndAS) as prescribed under section 133 of the companies Act, 2013 read with the companies (Indian Accounting Standards) Rules, 2015 (as amended)

2. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
 Date : 14.11.2018



For VIVIMED LABS LIMITED

 (SANTOSH VARALWAR)
 MANAGING DIRECTOR

VIVIMED LABS LIMITED

SEGMENT-WISE STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER'2018

Rs in Lakhs

Particulars	3 Months Ended			FY 19 H1	FY 18 H1	FY 18
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue <i>(net sales/income from each segment should be disclosed under this head)</i>						
a.Speciality Chemicals Business	2,093.28	1,769.29	1,678.48	3,862.58	3,339.43	7,161.20
b.Pharma Business	4,257.21	4,429.24	4,436.17	8,686.44	9,410.81	18,977.38
Total	6,350.49	6,198.53	6,114.65	12,549.02	12,750.24	26,138.58
Less: Inter Segment Revenue						
Net sales / Income from Operations	6,350.49	6,198.53	6,114.65	12,549.02	12,750.24	26,138.58
2.Segment Results (Profit) (+) / Loss (-) <i>before tax and interest from each segment</i>						
a.Speciality Chemicals Business	446.53	411.27	570.18	857.80	730.51	2,037.46
b.Pharma Business	824.99	886.92	939.36	1,711.92	2,197.97	4,027.96
Total	1,271.52	1,298.19	1,509.54	2,569.71	2,928.48	6,065.42
Less: 1.Interest	1,156.68	1,138.70	1,297.55	2,295.38	2,512.51	5,180.22
2.Other Un-allocable Expenditure						
3.Un-allocable Income						
Total Profit Before Tax	114.84	159.49	211.99	274.33	415.97	885.20

Segmental capital employed

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeability across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Place : Hyderabad

Date : 14.11.2018



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR

Vivimed Labs Limited Balance Sheet (All amounts in Indian Rupees Lakhs, except share data and where otherwise stated)		Rs in Lakhs		
	Standalone		Consolidated	
	As at 30 September 2018	As at 31 March 2018	As at 30 September 2018	As at 31 March 2018
ASSETS				
Non current assets				
Property, Plant and Equipment	38,551.99	35,664.35	79,503.59	74,471.60
Intangible assets	4,887.61	4,818.65	32,689.83	29,064.00
Capital work in progress	4,559.08	4,277.64	10,986.85	6,527.14
Financial assets	-	-	-	-
Investments	15,186.57	15,186.57	251.00	269.92
Deferred tax assets, net	-	-	529.57	785.73
Other non-current assets	-	-	202.65	50.31
Total non current assets	63,185.25	59,947.21	1,24,163.50	1,11,168.70
Current assets				
Inventories	25,452.59	29,253.99	51,414.24	54,016.56
Financial assets	-	-	-	-
Trade receivables	17,746.94	16,767.12	32,793.79	27,542.97
Cash and cash equivalents	767.76	917.85	6,346.40	9,903.30
Loans	4,558.90	5,821.07	10,268.11	8,471.40
Others	357.55	254.84	10.79	7.81
Current tax assets, net	-	-	1,158.43	3,241.70
Other current assets	16,563.78	12,579.31	33,942.69	25,010.32
Total current assets	65,447.52	65,594.18	1,35,934.45	1,28,194.06
Total assets	1,28,632.77	1,25,541.39	2,60,097.95	2,39,362.76
EQUITY AND LIABILITIES				
Equity				
Equity share capital	1,650.48	1,650.48	1,650.48	1,650.48
Instruments entirely equity in nature	-	-	32,522.05	32,522.05
Other equity	55,669.06	55,090.47	88,194.66	88,467.23
Total equity	57,319.54	56,740.95	1,22,367.19	1,22,639.76
Non-controlling interests	-	-	1,228.11	1,228.11
Non current liabilities				
Financial Liabilities				
Borrowings	8,811.16	11,595.66	40,217.65	32,519.63
Others	17,148.26	13,528.50	1,584.92	2,335.96
Deferred tax liabilities, net	1,266.52	1,333.54	-	-
Other Non current liabilities	979.90	1,653.89	3,157.11	913.40
Provisions	781.19	716.90	767.03	702.74
Total non current liabilities	28,987.03	28,828.49	45,726.71	36,471.73
Current liabilities				
Financial Liabilities				
Borrowings	24,970.91	25,870.39	41,325.87	38,516.12
Trade payables	5,160.69	2,338.64	28,986.80	20,199.37
Other financial liabilities	7,925.44	7,599.61	13,583.89	13,981.62
Other current liabilities	202.71	77.61	1,103.27	782.84
Provisions	-	55.24	-	55.24
Current tax liabilities	4,066.45	4,030.46	5,776.11	5,487.97
Total liabilities	42,326.20	39,971.95	90,775.94	79,023.16
Total equity and liabilities	1,28,632.77	1,25,541.39	2,60,097.95	2,39,362.76





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

LIMITED REVIEW REPORT-CONSOLIDATED FINANCIAL RESULTS

To


The Board of Directors,

M/s. Vivimed Labs Limited,

Hyderabad

Limited Review Report for the quarter and half year ended 30th September, 2018

1. We have reviewed the accompanying statement of unaudited Consolidated financial results ("the Statement") of M/s. Vivimed Labs Limited Group comprising M/s. Vivimed Labs Limited ("the Company") and its subsidiaries (together referred to as 'the group'), for the quarter ended 30th September, 2018 and year to date from April 1st 2018 to September 30th 2018 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5th 2016.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5th 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14th November, 2018. Our responsibility is to issue a report on the statement based on our review.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates.,
(Formerly known as Chandra Babu Naidu & Co.,)
Chartered Accountants.,

FRN: 016016S

Chandra Babu MN

Partner

M.No. 227849



Place: Hyderabad

Date: 14th November 2018



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.


Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

LIMITED REVIEW REPORT-STANDALONE FINANCIAL RESULTS

To
The Board of Directors
Vivimed Labs Limited
Hyderabad

Limited Review Report for the quarter and half year ended 30th September, 2018

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. **Vivimed Labs Limited** for the quarter ended 30th September, 2018 and year to date from April 1st 2018 to September 30th 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 14th November, 2018. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.







P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results prepared in accordance with applicable Ind AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P C N & Associates.,
(Formerly known as Chandra Babu Naidu & Co.,)
Chartered Accountant
FRN:016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date : 14th November, 2018